Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical...

Area of Science:

• Preclinical research
• Translational medicine
• Inflammatory bowel disease (IBD) modeling

Background:

• Therapeutic agents are typically developed and tested in animal models to assess safety, dose-response, and efficacy.
• A significant gap exists between promising preclinical findings and clinical efficacy, with low translation rates.
• Shortcomings in preclinical study design are increasingly recognized as a major contributor to this translational failure.

Purpose of the Study:

• To critically evaluate existing mouse models for inflammatory bowel disease (IBD) that closely mimic the human clinical situation.
• To assess pharmacological strategies used in preclinical intervention studies for their relevance to human IBD treatment.
• To discuss emerging issues in study design and data interpretation for preclinical research in IBD.

Main Methods:

• Review and critical evaluation of published literature on mouse models of IBD.
• Analysis of pharmacological approaches employed in preclinical IBD intervention studies.
• Discussion of study design principles and data interpretation challenges in preclinical research.

Main Results:

• Identifies specific mouse models and pharmacological strategies that offer greater immunological relevance to human IBD.
• Highlights common deficiencies in the design and execution of preclinical IBD studies.
• Underscores the need for improved study design to enhance the predictive value of animal models.

Conclusions:

• Selecting immunologically relevant mouse models and appropriate pharmacological strategies is crucial for successful therapeutic development in IBD.
• Addressing limitations in preclinical study design is essential to bridge the gap between bench and bedside discoveries.
• Improved preclinical research practices will increase the likelihood of identifying effective treatments for human inflammatory bowel disease.